Future treatment of osteoarthritis.
Osteoarthritis represents an advanced stage of disease progression caused in part by injury, loss of cartilage structure and function, and an imbalance in inflammatory and noninflammatory pathways. The burden of this disease will increase in direct proportion to the increase in the older adult population. Research on current and experimental treatment protocols are reviewed, including the effect of hyaluronic acid in both in vitro and in vivo studies, autologous chondrocyte and osteochondral plug implantation, and gene therapy. Disease-modifying osteoarthritis drugs and in vivo studies of glucosamine and chondroitin sulfate are reviewed.
Baker
Champ L
CL
Hughston Clinic, PC, Columbus, Ga, USA.
Ferguson
Cristin M
CM
D000276:Adjuvants, Immunologic / Q000493:pharmacokinetics / Q000627:therapeutic use; D000880:Anthraquinones / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D028241:Camellia sinensis; D002358:Cartilage, Articular / Q000637:transplantation; D019902:Chondrocytes / Q000637:transplantation; D002807:Chondroitin / Q000627:therapeutic use; D005544:Forecasting; D015316:Genetic Therapy; D005944:Glucosamine / Q000627:therapeutic use; D006801:Humans; D006820:Hyaluronic Acid / Q000493:pharmacokinetics / Q000627:therapeutic use; D010003:Osteoarthritis / Q000188:drug therapy* / Q000601:surgery; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000880:Anthraquinones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D010936:Plant Extracts; C465546:green tea extract AR25; C025292:diacerein; D006820:Hyaluronic Acid; D002807:Chondroitin; D005944:Glucosamine